To print: Select File and then Print from your browser's menu
---------------------------------------------------------------------------------------
Title: Alternatives for Radiation of Low-Grade Glioma Prove Effective in Paediatric Patients
URL: http://www.pslgroup.com/dg/22E3FA.htm
Doctor's Guide
October 6, 2008

HOUSTON, Tex -- October 6, 2008 -- Using chemotherapy alone and delaying or avoiding cranial radiation altogether can be effective in treating paediatric patients with unresectable or progressive low-grade glioma, according to a study presented at the 40th Congress of the International Society of Paediatric Oncology in Berlin, Germany.

Low-grade glioma is the most common brain tumour in children. If eligible for surgery, overall survival rate for these children is 95%. However, for patients with tumours in locations that prevent surgical removal or whose tumour is progressive after surgery, prognosis is worse.

A majority of paediatric oncologists use cranial radiation to treat patients with unresectable or progressive brain tumours. Although radiation is often effective, the long-term effects such as mental impairment, hormonal deficiencies, and increased rate of stroke late in life can be detrimental to young patients -- causing some physicians and families to decide against treatment.

"This is the first large, multi-institutional study to investigate using chemotherapy as an alternative to cranial radiation," says Joann Ater, MD, Children's Cancer Hospital, University of Texas M. D. Anderson Cancer Center, Houston, Texas. "The results have confirmed the ability of chemotherapy to control the disease."

Dr. Ater is the principal investigator for the Children's Oncology Group (COG) study and developed the phase 3 trial, which compared 2 different chemotherapy regimens across 3 different patient groups.

Smaller pilot studies have shown a carboplatin and vincristine (CV) regimen to be effective against low-grade glioma. However, the COG trial with 401 patients enrolled showed that a thioguanine, procarbazine, lomustine, and vincristine (TPCV) regimen was more effective than the CV regimen and resulted in a 5-year event-free survival rate of nearly 50%.

Patients aged younger than 5 years averaged 2.2 years before the disease progressed on the CV regimen, while patients aged between 5 to 10 years averaged 5.3 years before disease progression.

Patients on the TPCV regimen fared better, with those aged 5 to 10 years averaging more than 8 years without disease progression. The trial also studied chemotherapy for neurofibromatosis patients who had low-grade gliomas. This patient population had the best response to chemotherapy among the 3 groups.

"If we can delay radiation, then we allow more time for our youngest patients to develop physically, which could decrease some of the long-term effects from treatment," said Dr. Ater. "This trial at least gives parents more information and alternative options when making decisions about their child's treatment."

SOURCE: University of Texas M. D. Anderson Cancer Center

---------------------------------------------------------------------------------------------
Copyright © 1999 P\S\L Consulting Group Inc. All rights reserved. Republication or redistribution of P\S\L content is expressly prohibited without the prior written consent of P\S\L. P\S\L shall not be liable for any errors, omissions or delays in this content or any other content on its sites, newsletters or other publications, nor for any decisions or actions taken in reliance on such content.
---------------------------------------------------------------------------------------------
This news story was printed from *Doctor's Guide to the Internet*
located at http://www.docguide.com
---------------------------------------------------------------------------------------

Return to News Story Page

This site is maintained by webmaster@pslgroup.com
Please contact us with any comments, problems or bugs.
All contents Copyright (c) 1998 P\S\L Consulting Group Inc.
All rights reserved.